NO20005254D0 - Kinolindervater - Google Patents

Kinolindervater

Info

Publication number
NO20005254D0
NO20005254D0 NO20005254A NO20005254A NO20005254D0 NO 20005254 D0 NO20005254 D0 NO 20005254D0 NO 20005254 A NO20005254 A NO 20005254A NO 20005254 A NO20005254 A NO 20005254A NO 20005254 D0 NO20005254 D0 NO 20005254D0
Authority
NO
Norway
Prior art keywords
vater
linder
cinema
linder vater
cinema linder
Prior art date
Application number
NO20005254A
Other languages
English (en)
Other versions
NO20005254L (no
NO315606B1 (no
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO20005254D0 publication Critical patent/NO20005254D0/no
Publication of NO20005254L publication Critical patent/NO20005254L/no
Publication of NO315606B1 publication Critical patent/NO315606B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20005254A 1998-04-27 2000-10-19 Kinolinderivater NO315606B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives

Publications (3)

Publication Number Publication Date
NO20005254D0 true NO20005254D0 (no) 2000-10-19
NO20005254L NO20005254L (no) 2000-12-27
NO315606B1 NO315606B1 (no) 2003-09-29

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005254A NO315606B1 (no) 1998-04-27 2000-10-19 Kinolinderivater

Country Status (33)

Country Link
EP (1) EP1073639B1 (no)
JP (1) JP4045069B2 (no)
KR (1) KR100571534B1 (no)
CN (1) CN1113057C (no)
AP (1) AP1293A (no)
AT (1) ATE228505T1 (no)
AU (1) AU747550B2 (no)
BR (1) BR9909925B1 (no)
CA (1) CA2329788C (no)
CZ (1) CZ297439B6 (no)
DE (1) DE69904162T2 (no)
DK (1) DK1073639T3 (no)
EE (1) EE04275B1 (no)
ES (1) ES2188242T3 (no)
HK (1) HK1036618A1 (no)
HR (1) HRP20000726B1 (no)
HU (1) HU227709B1 (no)
ID (1) ID26277A (no)
IL (2) IL138160A0 (no)
IS (1) IS2082B (no)
ME (1) ME00870B (no)
NO (1) NO315606B1 (no)
NZ (1) NZ506641A (no)
OA (1) OA11547A (no)
PL (1) PL190441B1 (no)
PT (1) PT1073639E (no)
RS (1) RS50029B (no)
RU (1) RU2197481C2 (no)
SE (1) SE9801474D0 (no)
TR (1) TR200003061T2 (no)
UA (1) UA60354C2 (no)
WO (1) WO1999055678A1 (no)
ZA (1) ZA200004601B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0516383A (pt) 2004-12-21 2008-09-02 Serono Lab derivados cìclicos de sulfonil amino e o uso dos mesmos
EP1844032B1 (en) 2005-01-31 2011-07-13 Merck Serono SA N-hydroxyamide derivatives and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
UA92761C2 (ru) * 2005-10-19 2010-12-10 Тева Фармасьютикл Индастриз, Лтд. Кристаллы лаквинимода натрия и способ их изготовления
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EA021227B1 (ru) * 2008-09-03 2015-05-29 Тева Фармасьютикал Индастриз Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
DK2467372T3 (en) * 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
PT2542079E (pt) 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
PE20130613A1 (es) 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
ES2563208T3 (es) * 2010-07-09 2016-03-11 Active Biotech Ab Método para fabricar quinolina-3-carboxamidas
US20120010239A1 (en) * 2010-07-09 2012-01-12 Ulf Tomas Fristedt 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
AU2014216199A1 (en) * 2013-02-15 2015-09-03 Teva Pharmaceutical Industries Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
MX2017006110A (es) 2014-11-19 2017-07-27 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
CA3157394A1 (en) 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
MX2022010327A (es) 2020-03-03 2022-11-09 Active Biotech Ab Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada.
CA3185531A1 (en) 2020-07-23 2022-01-27 Rebekka Katharina Marita SCHNEIDER-KRAMANN S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
IL309486A (en) 2021-07-02 2024-02-01 Active Biotech Ab A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
CA2329788A1 (en) 1999-11-04
AU747550B2 (en) 2002-05-16
CA2329788C (en) 2004-11-23
HUP0102084A3 (en) 2002-12-28
WO1999055678A1 (en) 1999-11-04
PL190441B1 (pl) 2005-12-30
CN1113057C (zh) 2003-07-02
RU2197481C2 (ru) 2003-01-27
ME00870B (me) 2008-11-28
EP1073639A1 (en) 2001-02-07
NZ506641A (en) 2002-03-28
CZ20003849A3 (cs) 2001-03-14
TR200003061T2 (tr) 2001-01-22
AP2000001933A0 (en) 2000-12-31
NO20005254L (no) 2000-12-27
RS50029B (sr) 2008-11-28
YU61200A (sh) 2003-07-07
EP1073639B1 (en) 2002-11-27
EE200000613A (et) 2002-04-15
DK1073639T3 (da) 2003-03-24
BR9909925A (pt) 2001-01-09
HUP0102084A2 (hu) 2001-11-28
CZ297439B6 (cs) 2006-12-13
NO315606B1 (no) 2003-09-29
DE69904162T2 (de) 2003-08-21
ID26277A (id) 2000-12-14
ATE228505T1 (de) 2002-12-15
IS5615A (is) 2000-08-31
HU227709B1 (en) 2011-12-28
JP4045069B2 (ja) 2008-02-13
BR9909925B1 (pt) 2010-09-21
HRP20000726B1 (en) 2009-04-30
PT1073639E (pt) 2003-04-30
HRP20000726A2 (en) 2001-04-30
ES2188242T3 (es) 2003-06-16
IL138160A (en) 2006-04-10
JP2002513006A (ja) 2002-05-08
KR100571534B1 (ko) 2006-04-14
CN1298393A (zh) 2001-06-06
AU4301399A (en) 1999-11-16
DE69904162D1 (de) 2003-01-09
IS2082B (is) 2006-02-15
IL138160A0 (en) 2001-10-31
AP1293A (en) 2004-08-30
OA11547A (en) 2004-05-24
PL343420A1 (en) 2001-08-13
ZA200004601B (en) 2002-02-27
EE04275B1 (et) 2004-04-15
SE9801474D0 (sv) 1998-04-27
UA60354C2 (uk) 2003-10-15
HK1036618A1 (en) 2002-01-11

Similar Documents

Publication Publication Date Title
NO20005254L (no) Kinolindervater
ATE341990T1 (de) Sigmidoskop
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
FI981234A (fi) Suuntauslaite
IT1312540B1 (it) Composto.
DE59907306D1 (de) Fadenchangierung
DE59906931D1 (de) Exzenterzahnradgetriebe
DE59910394D1 (de) Gesinterter stiftheizer
DE29816928U1 (de) Stepper
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908968D1 (de) Benzoylpyridazine
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE19842103B4 (de) Stanznietzuführung
DE59808995D1 (de) Endomikroskopsystem
DE59902088D1 (de) Achrathermer Reimager
DE59903616D1 (de) Rollenwicklerwalze
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
PT1076660E (pt) (4-bromopirazol-3-il)-benzazolos substituidos
DE59910289D1 (de) Friktionsdrallvorrichtung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees